Dimopoulos MA, et al. - By pooling data from four newly diagnosed multiple myeloma (NDMM) phase I/II studies, researchers assessed ixazomib (oral proteasome inhibitor) for safety and efficacy as maintenance therapy in patients with NDMM not undergoing transplantation. Until disease progression, death, or unacceptable toxicity, patients were treated with induction therapy with once- or twice-weekly ixazomib plus lenalidomide-dexamethasone, melphalan-prednisone, or cyclophosphamide-dexamethasone, and thereafter single-agent ixazomib maintenance, given at the last tolerated dose during induction. In these patients, a deepening of responses was observed in relation to ixazomib maintenance following ixazomib-based induction, with a positive safety profile and no cumulative toxicity. Findings established the feasibility of ixazomib for long-term administration.